UroGen Pharma Statistics
Total Valuation
UroGen Pharma has a market cap or net worth of $858.88 million. The enterprise value is $823.22 million.
Important Dates
The last earnings date was Thursday, August 7, 2025, before market open.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
UroGen Pharma has 46.20 million shares outstanding. The number of shares has increased by 29.37% in one year.
| Current Share Class | 46.20M |
| Shares Outstanding | 46.20M |
| Shares Change (YoY) | +29.37% |
| Shares Change (QoQ) | +0.67% |
| Owned by Insiders (%) | 5.12% |
| Owned by Institutions (%) | 91.27% |
| Float | 36.80M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.33 |
| Forward PS | 6.87 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 8.74 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.14
| Current Ratio | 4.14 |
| Quick Ratio | 3.71 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.27 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -31.21% |
| Return on Invested Capital (ROIC) | -94.56% |
| Return on Capital Employed (ROCE) | -75.99% |
| Revenue Per Employee | $401,013 |
| Profits Per Employee | -$659,438 |
| Employee Count | 235 |
| Asset Turnover | 0.38 |
| Inventory Turnover | 1.48 |
Taxes
In the past 12 months, UroGen Pharma has paid $4.15 million in taxes.
| Income Tax | 4.15M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +22.63% in the last 52 weeks. The beta is 1.13, so UroGen Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.13 |
| 52-Week Price Change | +22.63% |
| 50-Day Moving Average | 13.38 |
| 200-Day Moving Average | 11.42 |
| Relative Strength Index (RSI) | 60.67 |
| Average Volume (20 Days) | 1,342,914 |
Short Selling Information
The latest short interest is 7.29 million, so 15.79% of the outstanding shares have been sold short.
| Short Interest | 7.29M |
| Short Previous Month | 5.45M |
| Short % of Shares Out | 15.79% |
| Short % of Float | 19.82% |
| Short Ratio (days to cover) | 3.28 |
Income Statement
In the last 12 months, UroGen Pharma had revenue of $94.24 million and -$154.97 million in losses. Loss per share was -$3.28.
| Revenue | 94.24M |
| Gross Profit | 83.43M |
| Operating Income | -122.47M |
| Pretax Income | -100.36M |
| Net Income | -154.97M |
| EBITDA | -122.18M |
| EBIT | -122.47M |
| Loss Per Share | -$3.28 |
Full Income StatementBalance Sheet
The company has $156.95 million in cash and $125.92 million in debt, giving a net cash position of $35.67 million or $0.77 per share.
| Cash & Cash Equivalents | 156.95M |
| Total Debt | 125.92M |
| Net Cash | 35.67M |
| Net Cash Per Share | $0.77 |
| Equity (Book Value) | -93.38M |
| Book Value Per Share | -2.02 |
| Working Capital | 149.32M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$123.13 million and capital expenditures -$396,000, giving a free cash flow of -$123.53 million.
| Operating Cash Flow | -123.13M |
| Capital Expenditures | -396,000 |
| Free Cash Flow | -123.53M |
| FCF Per Share | -$2.67 |
Full Cash Flow StatementMargins
Gross margin is 88.54%, with operating and profit margins of -129.95% and -164.44%.
| Gross Margin | 88.54% |
| Operating Margin | -129.95% |
| Pretax Margin | -160.04% |
| Profit Margin | -164.44% |
| EBITDA Margin | -129.65% |
| EBIT Margin | -129.95% |
| FCF Margin | n/a |
Dividends & Yields
UroGen Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -29.37% |
| Shareholder Yield | -29.37% |
| Earnings Yield | -18.04% |
| FCF Yield | -14.38% |
Analyst Forecast
The average price target for UroGen Pharma is $29.00, which is 56.00% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $29.00 |
| Price Target Difference | 56.00% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
